Theralase Technologies Inc. (CVE:TLT - Get Free Report) hit a new 52-week high on Monday . The company traded as high as C$2.18 and last traded at C$0.21, with a volume of 49500 shares. The stock had previously closed at C$0.20.
Theralase Technologies Stock Performance
The company has a market capitalization of C$48.70 million, a P/E ratio of -10.65 and a beta of 1.36. The company has a debt-to-equity ratio of 14.85, a current ratio of 1.91 and a quick ratio of 3.40. The stock's 50 day simple moving average is C$0.19 and its two-hundred day simple moving average is C$0.23.
About Theralase Technologies
(
Get Free Report)
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Further Reading
Before you consider Theralase Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theralase Technologies wasn't on the list.
While Theralase Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
